Advanced search
Publication Cover
Cancer Investigation Volume 16, 1998 - Issue 2
Submit an article Journal homepage
50
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Efficacy of Intravenous Granisetron to Control Nausea and Vomiting During Multiple Cycles of Cisplatin-Based Chemotherapy

Howard L. Ritter Toledo Clinic, Inc. Hematology-Oncology Department, 4235 Secor Road, Toledo, Ohio, 43623
,
Richard J. Gralla Alton Ochsner Medical Foundation, 1516 Jefferson Highway, New Orleans, Louisiana, 70121
,
Stephen W. Hall University of Nevada School of Medicine-Reno VA Medical Center, 1000 Locust Street, Reno, Nevada, 89520
,
J. K. Wada Glendale Memorial Hospital, 435 Arden Avenue, Suite 520, Glendale, California, 91203
,
Carl Friedman Clinical Research, Development and Medical Affairs, North America SmithKline Beecham Pharmaceuticals, PO Box 5089, Collegeville, Pennsylvania, 19426-0989
,
Linda Hand Clinical Research, Development and Medical Affairs, North America SmithKline Beecham Pharmaceuticals, PO Box 5089, Collegeville, Pennsylvania, 19426-0989
&
David Fitts Clinical Research, Development and Medical Affairs, North America SmithKline Beecham Pharmaceuticals, PO Box 5089, Collegeville, Pennsylvania, 19426-0989
 show all
Pages 87-93 | Published online: 11 Jun 2009

References

  • Love R R, Leventhal H, Easterling D V, et al. Side effects and emotional distress during cancer chemotherapy. Cancer 1989; 63: 604–612
  • Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs 1983; 25(Suppl 1)1–7
  • Hesketh P J, Gandara D R. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991; 83: 613–620
  • Alba E, Bastus R, De Andres L, et al. Anticipatory nausea and vomiting: prevalence and predictors in chemotherapy patients. Oncology 1989; 63: 604–612
  • Kris M G, Gralla R J, Clark R A, et al. Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3: 1379–1384
  • Morrow G R. Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 1982; 68: 585–588
  • Miner W D, Sanger G J. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986; 88: 497
  • Chevallier B. The control of acute cisplatin-induced emesis—A comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Br J Cancer 1993; 68: 176–180
  • Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 1990; 26(Suppl 1)S33–S36
  • Cupissol D R, Serrou B, Caubel M. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer 1990; 26: S23–S27
  • Falkson H C, Falkson C I, Falkson G. High versus low dose granisetron, a selective 5-HT3 antagonist, for the prevention of chemotherapy-induced nausea and vomiting. Invest New Drugs 1990; 8: 407–409
  • De Mulder P HM, Seynaeve C, Vermorken J B, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113: 834–840
  • Grunberg S M, Stevenson I X, Russell C A, et al. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989; 7: 1137–1141
  • Jantunen I T, Muhonen T T, Kataja V V, et al. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—a randomised study. Eur J Cancer 1993; 29A: 1669–1672
  • Kamanabrou D. Intravenous granisetron-Establishing the optimal dose. Eur J Cancer 1992; 28A(Suppl 1)S6–S11
  • Marty M, Pouillart P, Scholl S, et al. Comparison of the 5-hydroxytryptamines (serotonin) receptor antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 322: 816–821
  • Marty M. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cyto-static-induced emesis. Eur J Cancer 1990; 26(Suppl 1)S28–S32
  • Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995; 13: 1242–1248
  • Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9: 675–678
  • Sledge G W, Jr, Einhorn L, Nagy C, et al. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 1992; 70: 2524–2528
  • Soukop M. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer 1990; 26(Suppl 1)S15–S19
  • Navari R M, Kaplan H G, Gralla R J, et al. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994; 12: 2204–2210
  • Blijham G H. on behalf of the Granisetron Study Group: Does granisetron remain effective over multiple cycles?. Eur J Cancer 1992; 28A(Suppl 1)S17–21
  • Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: A review. Ann Oncol 1991; 2: 107–114

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.